Acid Treated Montmorillonite—Eco-Friendly Clay as Catalyst in Carvone Isomerization to Carvacrol

Acid-treated montmorillonites (MMT) were used as catalysts of carvone isomerization to carvacrol. Mineral acids—sulfuric, hydrochloric, nitric acids and organic acids (acetic and chloroacetic)—were used for the acid treatment. Prepared materials were characterized by available characterization methods, namely XRD, EA, TPD, TPO, UV-Vis, laser light scattering and nitrogen physisorption. The structure of montmorillonite remained intact after treatment. However, TPD proved the increase of acidity of acid-treated materials comparing pure montmorillonite. All materials were tested in the isomerization of carvone, producing carvacrol as the desired product. The initial reaction rate increased using the materials in the row MMT-COOH 3 2SO4 < MMT-HCl, which is in accordance with the pKa of acids used for the treatment. The number of weak acid sites strongly influenced the selectivity to carvacrol. The optimal solvent for the reaction was toluene. Total conversion of carvone and the selectivity to carvacrol 95.5% was achieved within 24 h under 80 °C, with toluene as solvent and montmorillonite treated by chloroacetic acid as catalyst. The catalyst may be reused after calcination with only a low loss of activity

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model

Although posaconazole tablets show relatively low variability in pharmacokinetics (PK), the proportion of patients achieving the PK/PD target at the approved uniform dose for both prophylaxis and therapy is not satisfactory. The aim of this study was to develop a posaconazole population PK model in lung-transplant recipients and to propose a covariate-based dosing optimization for both prophylaxis and therapy. In this prospective study, 80 posaconazole concentrations obtained from 32 lung-transplant patients during therapeutic drug monitoring were analyzed using nonlinear mixed-effects modelling, and a Monte Carlo simulation was used to describe the theoretical distribution of posaconazole PK profiles at various dosing regimens. A one-compartment model with both linear absorption and elimination best fit the concentration–time data. The population apparent volume of distribution was 386.4 L, while an apparent clearance of 8.8 L/h decreased by 0.009 L/h with each year of the patient’s age. Based on the covariate model, a dosing regimen of 200 mg/day for prophylaxis in patients ˃60 years, 300 mg/day for prophylaxis in patients ˂60 years and for therapy in patients ˃60 years, and 400 mg/day for therapy in patients ˂60 years has been proposed. At this dosing regimen, the PK/PD target for prophylaxis and therapy is reached in 95% and 90% of population, respectively, representing significantly improved outcomes in comparison with the uniform dose